<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052960</url>
  </required_header>
  <id_info>
    <org_study_id>GEXMab52201</org_study_id>
    <secondary_id>2013-000931-28</secondary_id>
    <nct_id>NCT02052960</nct_id>
  </id_info>
  <brief_title>CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer</brief_title>
  <acronym>RESGEX</acronym>
  <official_title>Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients&#xD;
      with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in&#xD;
      combination with platinum-based chemotherapy) in terms of progression-free survival (PFS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indication: First line systemic treatment for stage III/IV recurrent and/or metastatic&#xD;
      squamous cell carcinoma of the head and neck (SCCHN)&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV&#xD;
      recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with&#xD;
      platinum-based chemotherapy) in terms of progression-free survival (PFS).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To evaluate further efficacy criteria, safety and quality of life (QoL) of patients with&#xD;
      stage III/IV recurrent and/or metastatic SCCHN treated with CetuGEX™ as compared to cetuximab&#xD;
      (both in combination with platinum-based chemotherapy).&#xD;
&#xD;
      To assess pharmacokinetic (PK) parameters and profiles of CetuGEX™. To assess efficacy and&#xD;
      safety based on genetic markers for immune response (Fc-gamma receptor [FcγR] allotypes) and&#xD;
      biomarkers (exploratory only).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">October 4, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>The PFS was defined as time from randomization until disease progression or death of any cause, up to 24 month</time_frame>
    <description>The primary efficacy endpoint was PFS as assessed by the investigator. Date of disease progression was defined as the date of imaging (based on computed tomography (CT) scans or magnetic resonance imaging (MRI)) showing disease progression, as assessed by the investigator according to adapted immune-related RECIST 1.1 (modified irRC). Disease progression was defined as a 20% increase in tumor burden, taking as reference the smallest tumor burden recorded since the treatment started; confirmation by a second scan was not required. The PFS time was censored at the time of the last tumor assessment if the patient was alive and without progression at the last time of observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Time from randomization until disease progression or death, whichever occurs first, up to 24 month.</time_frame>
    <description>Objective response rate is the percentage of patients with a tumor size reduction of a predefined amount for a minimum time period and it is defined as the sum of complete responses (CR) and partial responses (PR).&#xD;
CR: Disappearance of all non-nodal target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt; 10 mm.&#xD;
Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (&lt; 10 mm short axis).&#xD;
PR: At least a 30% decrease in the tumor burden (sum of the longest lesion diameter (LD) of target lesions (including the short axes of any target lymph nodes plus measurable new lesions), taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>Time from randomization until disease progression or death, whichever occurs first, up to 24 month.</time_frame>
    <description>The clinical benefit rate is the percentage of patients with an objective response or stable disease (SD). SD is defined as not meeting criteria of complete response and partial response, in absence of meeting criteria for disease progression. Follow-up measurements must have met the SD criteria at least once after randomization at a minimum interval of 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Time to treatment failure, defined as the interval between the date of randomization and the date of treatment discontinuation for any reason, up to 24 month.</time_frame>
    <description>Time to treatment failure is defined as the time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from randomization to the time of death, up to 24 month.</time_frame>
    <description>The overall survival is defined as the duration of time from randomization to the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Global Health Status Deterioration</measure>
    <time_frame>From randomization up to end-of study visit, up to 24 month</time_frame>
    <description>Quality of Life (QoL) scores as assessed by European Oncology Research Trials Committee (EORTC) QoL questionnaires (QLQ) EORTC-QLQ-C30.&#xD;
Scores are on a scale of 0 to 100, where 100 represents the highest possible QoL.Time to first deterioration of at least 10 points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>CetuGEX™ plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>720 mg weekly administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab plus chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mg/m2 weekly administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CetuGEX™</intervention_name>
    <description>60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration</description>
    <arm_group_label>CetuGEX™ plus chemotherapy</arm_group_label>
    <other_name>Tomuzotuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration</description>
    <arm_group_label>Cetuximab plus chemotherapy</arm_group_label>
    <other_name>Erbitux®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)</description>
    <arm_group_label>CetuGEX™ plus chemotherapy</arm_group_label>
    <arm_group_label>Cetuximab plus chemotherapy</arm_group_label>
    <other_name>Combination of Cisplatin and 5-Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed recurrent and/or metastatic SCCHN not eligible&#xD;
             for local treatment.&#xD;
&#xD;
          2. Patients with measurable disease according to RECIST 1.1.&#xD;
&#xD;
          3. Patients aged at least 18 years at screening.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          5. Minimum life expectancy of 3 months.&#xD;
&#xD;
          6. Tissue samples available for specific and therapy-related biological assessments.&#xD;
&#xD;
          7. If female and of childbearing potential, was non-lactating and had negative pregnancy&#xD;
             test results at screening and prior to randomization.&#xD;
&#xD;
          8. If female, was either not of childbearing potential (defined as postmenopausal for at&#xD;
             least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy,&#xD;
             or hysterectomy]) or willing to use highly effective contraceptives during study&#xD;
             participation until 6 months after last administration of any study medication,&#xD;
             particularly cisplatin or carboplatin, with a failure rate &lt;1% according to the Note&#xD;
             for Guidance on non-clinical safety studies for the conduct of human clinical trials&#xD;
             and marketing authorization for pharmaceuticals (CPMP/ICH/286/95) of the European&#xD;
             Medicines Agency. Male patients who had partners of childbearing potential had to&#xD;
             confirm adequate use of highly effective contraceptives during study participation&#xD;
             until 6 months after last administration of any study medication, particularly&#xD;
             cisplatin or carboplatin, as well.&#xD;
&#xD;
          9. Willing and able to comply with the protocol.&#xD;
&#xD;
         10. Willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior systemic chemotherapy, except if given as part of a multimodal treatment for&#xD;
             locally advanced disease which was completed more than 6 months prior to&#xD;
             randomization.&#xD;
&#xD;
          2. Cetuximab or other epidermal growth factor receptor (EGFR)-targeting agent treatment,&#xD;
             except if given as part of a multimodal treatment for locally advanced disease which&#xD;
             was completed more than 6 months prior to randomization.&#xD;
&#xD;
          3. Surgery (other than minor interventions like diagnostic biopsy or intravenous port&#xD;
             implantation) or irradiation within 30 days before randomization.&#xD;
&#xD;
          4. Concomitant antitumor therapy or concomitant immunotherapy, live vaccines including&#xD;
             yellow fever vaccination (as per cisplatinum Summary of Product Characteristics&#xD;
             [SmPC]).&#xD;
&#xD;
          5. Concomitant corticosteroid treatment unless specified within the protocol.&#xD;
&#xD;
          6. Clinical evidence of brain metastasis or leptomeningeal involvement.&#xD;
&#xD;
          7. Patients with nasopharyngeal tumors.&#xD;
&#xD;
          8. Concomitant malignant disease, except for adequately treated tumors with high&#xD;
             likelihood of being cured (e.g., basal cell cancer of the skin, cervical cancer or&#xD;
             breast cancer in situ). Patients with previous malignancies but without evidence of&#xD;
             disease for at least 5 years were allowed to enter the study.&#xD;
&#xD;
          9. Patients with renal or hepatic impairment (serum creatinine and bilirubin &gt;1.5 fold&#xD;
             above the upper limit of normal ranges, creatinine clearance &lt;60 mL/min, and&#xD;
             transaminase &gt;5-fold above the upper limit of normal ranges) and patients with&#xD;
             hematology parameters outside the normal ranges (hemoglobin &lt;9 g/dL, absolute&#xD;
             neutrophil count &lt;1500/mm3 and platelet count &lt;105/mm3) at screening as well as&#xD;
             patients with impaired auditory function or platinum-related neuropathy.&#xD;
&#xD;
         10. Clinically active infections ≥Grade 2 using National Cancer Institute (NCI) Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) version 4 and/or requiring intravenous&#xD;
             antibiotics.&#xD;
&#xD;
         11. Known active hepatitis B or C.&#xD;
&#xD;
         12. Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         13. Myocardial infarction within 6 months prior to screening.&#xD;
&#xD;
         14. Symptomatic congestive heart failure (New York Heart Association Grade 3 or 4),&#xD;
             unstable angina pectoris within 6 months prior to screening, significant cardiac&#xD;
             arrhythmia, history of stroke, or transient ischemic attack within 1 year prior to&#xD;
             screening.&#xD;
&#xD;
         15. History of keratitis requiring medical interventions within the last 5 years or&#xD;
             interstitial lung disease.&#xD;
&#xD;
         16. Patients with any other disorder that, in the opinion of the investigator, might have&#xD;
             interfered with the conduct of the study.&#xD;
&#xD;
         17. Patients with an unstable condition (e.g., psychiatric disorder, a recent history of&#xD;
             drug or alcohol abuse, interfering with study compliance, within 6 months prior to&#xD;
             screening) or otherwise thought to be unreliable or incapable of complying with the&#xD;
             requirements of the protocol.&#xD;
&#xD;
         18. Patients institutionalized by official means or court order.&#xD;
&#xD;
         19. Receipt of any other IMP within the last 30 days before randomization or any previous&#xD;
             CetuGEX™ administration.&#xD;
&#xD;
         20. Prior allergic reaction to a monoclonal antibody, grade 3 infusion related reaction&#xD;
             (IRR) or any grade 4 reaction to a monoclonal antibody.&#xD;
&#xD;
         21. Known sensitivity to any component of the IMP and medication used in this study.&#xD;
&#xD;
         22. Known dihydropyrimidine dehydrogenase deficiency (France only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Keilholz, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facillity</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gycotope-contracted Research Facility</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Warsaw</city>
        <zip>2781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Brasov</city>
        <zip>500091</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Clui-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Craiova</city>
        <zip>200385</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Ploiesti</city>
        <zip>100011</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Timisoara</city>
        <zip>300167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracteed Research Facility</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Madrid</city>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope-contracted Research Facility</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <results_first_submitted>July 12, 2021</results_first_submitted>
  <results_first_submitted_qc>October 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tomuzotuximab</keyword>
  <keyword>cetuximab</keyword>
  <keyword>SCCHN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02052960/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02052960/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CetuGEX in Combination With Chemotherapy</title>
          <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly. Chemotherapy consisted of 5-FU (1000 mg/m2/d, day 1-4) and cisplatin (100 mg/m2, on day 1).Treatment cycles were scheduled to be repeated every 3 weeks for a maximum of 6 cycles, and followed by a weekly single-agent maintenance therapy of CetuGEX.</description>
        </group>
        <group group_id="P2">
          <title>Cetuximab in Combination With Chemotherapy</title>
          <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA. Chemotherapy consisted of 5-FU (1000 mg/m2/d, day 1-4) and cisplatin (100 mg/m2, on day 1).Treatment cycles were scheduled to be repeated every 3 weeks for a maximum of 6 cycles, and followed by a weekly single-agent maintenance therapy of cetuximab.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Patients</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intention-to-treat (ITT) population consisted of all randomized patients. The ITT population was the primary population for the efficacy analysis. The safety population included all patients who received at least 1 dose of trial medication (N=237). This population was used for safety analyses (adverse events).</population>
      <group_list>
        <group group_id="B1">
          <title>CetuGEX™ Plus Chemotherapy</title>
          <description>720 mg weekly administration&#xD;
CetuGEX™: 60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration&#xD;
Chemotherapy: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)</description>
        </group>
        <group group_id="B2">
          <title>Cetuximab Plus Chemotherapy</title>
          <description>250 mg/m2 weekly administration&#xD;
Cetuximab: 400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration&#xD;
Chemotherapy: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="7.54"/>
                    <measurement group_id="B2" value="59.8" spread="7.91"/>
                    <measurement group_id="B3" value="59.8" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Romania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="117"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>The primary efficacy endpoint was PFS as assessed by the investigator. Date of disease progression was defined as the date of imaging (based on computed tomography (CT) scans or magnetic resonance imaging (MRI)) showing disease progression, as assessed by the investigator according to adapted immune-related RECIST 1.1 (modified irRC). Disease progression was defined as a 20% increase in tumor burden, taking as reference the smallest tumor burden recorded since the treatment started; confirmation by a second scan was not required. The PFS time was censored at the time of the last tumor assessment if the patient was alive and without progression at the last time of observation.</description>
        <time_frame>The PFS was defined as time from randomization until disease progression or death of any cause, up to 24 month</time_frame>
        <population>Intent-to-treat-population</population>
        <group_list>
          <group group_id="O1">
            <title>CetuGEX</title>
            <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab</title>
            <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>The primary efficacy endpoint was PFS as assessed by the investigator. Date of disease progression was defined as the date of imaging (based on computed tomography (CT) scans or magnetic resonance imaging (MRI)) showing disease progression, as assessed by the investigator according to adapted immune-related RECIST 1.1 (modified irRC). Disease progression was defined as a 20% increase in tumor burden, taking as reference the smallest tumor burden recorded since the treatment started; confirmation by a second scan was not required. The PFS time was censored at the time of the last tumor assessment if the patient was alive and without progression at the last time of observation.</description>
          <population>Intent-to-treat-population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="25.3" upper_limit="33.7"/>
                    <measurement group_id="O2" value="26.4" lower_limit="24.9" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.736</ci_lower_limit>
            <ci_upper_limit>1.359</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Objective response rate is the percentage of patients with a tumor size reduction of a predefined amount for a minimum time period and it is defined as the sum of complete responses (CR) and partial responses (PR).&#xD;
CR: Disappearance of all non-nodal target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt; 10 mm.&#xD;
Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (&lt; 10 mm short axis).&#xD;
PR: At least a 30% decrease in the tumor burden (sum of the longest lesion diameter (LD) of target lesions (including the short axes of any target lymph nodes plus measurable new lesions), taking as reference the baseline sum diameters.</description>
        <time_frame>Time from randomization until disease progression or death, whichever occurs first, up to 24 month.</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>CetuGEX</title>
            <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab</title>
            <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Objective response rate is the percentage of patients with a tumor size reduction of a predefined amount for a minimum time period and it is defined as the sum of complete responses (CR) and partial responses (PR).&#xD;
CR: Disappearance of all non-nodal target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt; 10 mm.&#xD;
Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (&lt; 10 mm short axis).&#xD;
PR: At least a 30% decrease in the tumor burden (sum of the longest lesion diameter (LD) of target lesions (including the short axes of any target lymph nodes plus measurable new lesions), taking as reference the baseline sum diameters.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.5</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate</title>
        <description>The clinical benefit rate is the percentage of patients with an objective response or stable disease (SD). SD is defined as not meeting criteria of complete response and partial response, in absence of meeting criteria for disease progression. Follow-up measurements must have met the SD criteria at least once after randomization at a minimum interval of 8 weeks.</description>
        <time_frame>Time from randomization until disease progression or death, whichever occurs first, up to 24 month.</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>CetuGEX</title>
            <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab</title>
            <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate</title>
          <description>The clinical benefit rate is the percentage of patients with an objective response or stable disease (SD). SD is defined as not meeting criteria of complete response and partial response, in absence of meeting criteria for disease progression. Follow-up measurements must have met the SD criteria at least once after randomization at a minimum interval of 8 weeks.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.05</ci_lower_limit>
            <ci_upper_limit>9.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to treatment failure is defined as the time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.</description>
        <time_frame>Time to treatment failure, defined as the interval between the date of randomization and the date of treatment discontinuation for any reason, up to 24 month.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CetuGEX</title>
            <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab</title>
            <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to treatment failure is defined as the time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="17.0" upper_limit="25.7"/>
                    <measurement group_id="O2" value="23.3" lower_limit="16.1" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.814</ci_lower_limit>
            <ci_upper_limit>1.372</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The overall survival is defined as the duration of time from randomization to the time of death.</description>
        <time_frame>Time from randomization to the time of death, up to 24 month.</time_frame>
        <population>Intent-to-treat- population</population>
        <group_list>
          <group group_id="O1">
            <title>CetuGEX</title>
            <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab</title>
            <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The overall survival is defined as the duration of time from randomization to the time of death.</description>
          <population>Intent-to-treat- population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" lower_limit="40.7" upper_limit="73.9"/>
                    <measurement group_id="O2" value="59.0" lower_limit="52.9" upper_limit="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.734</ci_lower_limit>
            <ci_upper_limit>1.396</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Global Health Status Deterioration</title>
        <description>Quality of Life (QoL) scores as assessed by European Oncology Research Trials Committee (EORTC) QoL questionnaires (QLQ) EORTC-QLQ-C30.&#xD;
Scores are on a scale of 0 to 100, where 100 represents the highest possible QoL.Time to first deterioration of at least 10 points.</description>
        <time_frame>From randomization up to end-of study visit, up to 24 month</time_frame>
        <population>Intent-to treat population. 158 patients were evaluable for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CetuGEX in Combination With Chemotherapy</title>
            <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly. Chemotherapy consisted of 5-FU (1000 mg/m2/d, day 1-4) and cisplatin (100 mg/m2, on day 1).Treatment cycles were scheduled to be repeated every 3 weeks for a maximum of 6 cycles, and followed by a weekly single-agent maintenance therapy of CetuGEX.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab in Combination With Chemotherapy</title>
            <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA. Chemotherapy consisted of 5-FU (1000 mg/m2/d, day 1-4) and cisplatin (100 mg/m2, on day 1).Treatment cycles were scheduled to be repeated every 3 weeks for a maximum of 6 cycles, and followed by a weekly single-agent maintenance therapy of cetuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Global Health Status Deterioration</title>
          <description>Quality of Life (QoL) scores as assessed by European Oncology Research Trials Committee (EORTC) QoL questionnaires (QLQ) EORTC-QLQ-C30.&#xD;
Scores are on a scale of 0 to 100, where 100 represents the highest possible QoL.Time to first deterioration of at least 10 points.</description>
          <population>Intent-to treat population. 158 patients were evaluable for this Outcome Measure.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" lower_limit="14.0" upper_limit="61.4"/>
                    <measurement group_id="O2" value="31.3" lower_limit="11.7" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 24 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CetuGEX</title>
          <description>CetuGEX™ was administered as infusion to all patients randomized to the CetuGEX™ arm, once weekly. The initial dose was 990 mg and subsequent doses were 720 mg once weekly</description>
        </group>
        <group group_id="E2">
          <title>Cetuximab</title>
          <description>Cetuximab was administered once weekly as infusion to all patients randomized to the cetuximab arm.The initial dose was 400 mg/m2 body surface area (BSA) and each subsequent dose was 250 mg/m2 BSA.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="104" subjects_affected="44" subjects_at_risk="115"/>
                <counts group_id="E2" events="152" subjects_affected="56" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="105" subjects_affected="47" subjects_at_risk="115"/>
                <counts group_id="E2" events="124" subjects_affected="51" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="98" subjects_affected="33" subjects_at_risk="115"/>
                <counts group_id="E2" events="90" subjects_affected="37" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E2" events="69" subjects_affected="26" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="122" subjects_affected="58" subjects_at_risk="115"/>
                <counts group_id="E2" events="162" subjects_affected="63" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="73" subjects_affected="38" subjects_at_risk="115"/>
                <counts group_id="E2" events="84" subjects_affected="41" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="67" subjects_affected="35" subjects_at_risk="115"/>
                <counts group_id="E2" events="83" subjects_affected="41" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="115"/>
                <counts group_id="E2" events="40" subjects_affected="23" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="66" subjects_affected="26" subjects_at_risk="115"/>
                <counts group_id="E2" events="21" subjects_affected="12" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="82" subjects_affected="41" subjects_at_risk="115"/>
                <counts group_id="E2" events="81" subjects_affected="38" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="34" subjects_at_risk="115"/>
                <counts group_id="E2" events="75" subjects_affected="37" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="45" subjects_affected="24" subjects_at_risk="115"/>
                <counts group_id="E2" events="63" subjects_affected="36" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="83" subjects_affected="42" subjects_at_risk="115"/>
                <counts group_id="E2" events="72" subjects_affected="39" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="146" subjects_affected="53" subjects_at_risk="115"/>
                <counts group_id="E2" events="181" subjects_affected="51" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="47" subjects_affected="36" subjects_at_risk="115"/>
                <counts group_id="E2" events="48" subjects_affected="30" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" events="53" subjects_affected="22" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Neuropathy periphera</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="19" subjects_affected="9" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="116" subjects_affected="44" subjects_at_risk="115"/>
                <counts group_id="E2" events="127" subjects_affected="47" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="106" subjects_affected="30" subjects_at_risk="115"/>
                <counts group_id="E2" events="64" subjects_affected="21" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="38" subjects_affected="19" subjects_at_risk="115"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="40" subjects_affected="11" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="30" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication, presentation or use of the methods and/or results of the clinical trial are not permitted without prior written sponsor´s consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director Clinical Department</name_or_title>
      <organization>Glycotope GmbH</organization>
      <phone>0049309489 ext 2600</phone>
      <email>contact@glycotope.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

